InVision® platform
Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
InVisionFirst®Lung
Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients
Radar™
A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform
Our Mission
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Latest News and Events
Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ESMO Congress 2022
Inivata, a leader in liquid biopsy, alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence at the European Society for Medical Oncology (ESMO) Congress, taking place on 9-13 September 2022. Inivata and NeoGenomics, Inivata’s parent company, will host a joint booth in the exhibition hall at the conference. Read More
Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma
Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Pete Ellis, Kirsten McLay, Giovanni Marsico, Patricia Rojas, ... Read More
Changing Lives
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.
This is the story of the first patient Inivata tested.
